IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases New Stake in Illumina, Inc. (NASDAQ:ILMN)

IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 3,688 shares of the life sciences company’s stock, valued at approximately $493,000.

A number of other large investors have also added to or reduced their stakes in ILMN. WCM Investment Management LLC grew its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after buying an additional 27,618 shares during the period. Geode Capital Management LLC grew its position in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after buying an additional 48,018 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after acquiring an additional 54,319 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ILMN. Barclays reissued an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. Robert W. Baird cut their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Trading Down 2.8 %

Shares of ILMN stock opened at $80.00 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a fifty day simple moving average of $102.80 and a two-hundred day simple moving average of $126.79. The firm has a market capitalization of $12.67 billion, a PE ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.